Biomarkers
tumor
TUMOR
In part 1 phase 1b, 73 patients had evaluable samples for PD-L1 expression, including 31 (42.5%) with TC% ≥1% and 68 (93.2%) with IC% ≥1%. The relationships between PD-L1 expression, tumor response, and PFS in part 1 phase 1b are summarized in Supplementary Table 